As COVID-19 has proved once again, diseases do not recognise borders… So, with labs around the world on the race to find a vaccine, it is time to ask ourselves the question: What can the EU do to help? Is there a European added value concerning vaccination?

EPRS policy podcast - Towards a joint European approach on vaccination

Our longtime use - and abuse…- of antibiotics in humans, agricultural livestock management, and food production has led to an increased threat of antimicrobial resistance, making us all more vulnerable to infectious diseases… But what if the answer lied in probiotics?

EPRS STOA podcast - What if we could fight antibiotic resistance with probiotics?

The coronavirus crisis has highlighted the EU’s dependency on countries outside its borders for the production of many active pharmaceutical ingredients and medicines. It is not a new problem… but it has become painfully exposed in the past weeks. So, why is that? And what can the EU do about it? Never a debate has been timelier!

EPRS policy podcast - Addressing shortages of medicines

MEPs review the new US administration’s recent decision to pull back from a number of international organisations and agreements.

Following his inauguration on 20 January 2025, President Trump signed a large number of executive orders setting the priorities of the new US administration, including the country’s withdrawal from the World Health Organisation (WHO) and the Paris Agreement on climate change mitigation. Alongside Commission representatives, MEPs will discuss the impact of these decisions internationally and on the EU’s future involvement in these global initiatives.

Background

This is the second time the US has initiated the process of withdrawing from both the WHO and Paris Agreement.

During the first Trump administration (2017-2021), the US gave formal notice of withdrawal from the Paris Agreement in November 2019 (which then took 12 months to take effect). Shortly after taking office, President Biden revoked the decision, with the US formally rejoining the agreement in February 2021. President Trump also started the withdrawal process from the WHO in 2020, but it was never finalised and the decision was reversed by the Biden administration.

Debate on the US withdrawal from the Paris Climate Agreement, WHO and USaid

EP Plenary session - US withdrawal from the Paris Climate Agreement, the World Health Organisation and the suspension of US development and humanitarian aid

EP Mini-Plenary Session - Joint Debate - Pharmaceutical package

Press conference on EU options for improving access to medicines

An employer of Hungarian medicine factory Sanofi works in Veresegyhaz 35 kms from Budapest on July 16, 2012.

Health Related Matters

Following his inauguration on 20 January 2025, President Trump signed a large number of executive orders setting the priorities of the new US administration, including the country’s withdrawal from the World Health Organisation (WHO) and the Paris Agreement on climate change mitigation. Alongside Commission representatives, MEPs discuss the impact of these decisions internationally and on the EU’s future involvement in these global initiatives.

US withdrawal from the Paris Climate Agreement, the World Health Organisation and the suspension of US development and humanitarian aid: MEPs debate (part 1)

Following his inauguration on 20 January 2025, President Trump signed a large number of executive orders setting the priorities of the new US administration, including the country’s withdrawal from the World Health Organisation (WHO) and the Paris Agreement on climate change mitigation. Alongside Commission representatives, MEPs discuss the impact of these decisions internationally and on the EU’s future involvement in these global initiatives. This transcription is a result of an automatic process. Please check against delivery.

US withdrawal from the Paris Climate Agreement, the World Health Organisation and the suspension of US development and humanitarian aid: Closing statement by Hadja LAHBIB, European Commissioner for Equality, and European Commissioner for Preparedness

US withdrawal from the Paris Climate Agreement, the World Health Organisation and the suspension of US development and humanitarian aid: extracts from the debate

US withdrawal from the Paris Climate Agreement, the World Health Organisation and the suspension of US development and humanitarian aid: Opening statement by Hadja LAHBIB, European Commissioner for Equality, and European Commissioner for Preparedness

US withdrawal from the Paris Climate Agreement, the World Health Organisation and the suspension of US development and humanitarian aid: MEPs debate (part 3)

US withdrawal from the Paris Climate Agreement, the World Health Organisation and the suspension of US development and humanitarian aid: MEPs debate (part 2)

This infoclip illustrates the medication delivery process and drugs storage in pharmacies in Belgium, in the context of a surge of respiratory infections and the shortage of medication in Europe.

Infoclip: Drugs shortage in pharmacies

Many rare diseases manifest themselves in childhood, resulting in a shortened lifespan and leading to a dependency on care throughout the patients’ lives, causing significant suffering to the patients and their families. Patients affected by rare diseases often spend years enduring a “diagnostic odyssey” before receiving the correct diagnosis, if ever. Most rare diseases lack effective treatments representing an enormous unmet medical need. EU research and innovation is crucial to accelerate the discovery and development of novel therapeutics. Restrictions: ©The material may not be edited and must be shown entirely.

access to medicines (T)

Videot

Kuvat

Kuvagalleria

Äänitteet

Tapahtumat

Julkaistu media tälle tunniste

12

Videot

5

Kuvagalleria

3

Äänitteet

212

Kuvat

1

Tapahtumat